Comparison · NCT04777331-2fbad496
DBT Period: Prasinezumab vs DBT Period: Placebo: DBT Period: Number of Participants With Treatment Discontinuation Due to AEs
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. DBT Period: Prasinezumab vs DBT Period: Placebo: DBT Period: Number of Participants With Treatment Discontinuation Due to AEs. Trial comparisons, record NCT04777331-2fbad496. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04777331-2fbad496
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00685 | 0.00188 | 0.0246 | wilson | |
| Risk in group 2 | 0.0103 | 0.00352 | 0.03 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0035 | -0.0237 | 0.0155 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.662 | 0.111 | 3.93 | log | |
| Odds ratio, group 1 over group 2 | 0.66 | 0.109 | 3.98 | log | |
| Number needed to treat, for one fewer participant with the outcome on DBT Period: Prasinezumab than on DBT Period: Placebo | 286 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | DBT Period: Prasinezumab | Participants received prasinezumab, 1500 mg, as an IV infusion, Q4W up to at least 76 weeks. | 2 | 292 | OG001 |
| Group 2 | DBT Period: Placebo | Participants received prasinezumab matching placebo as an IV infusion, Q4W up to at least 76 weeks. | 3 | 290 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- DBT Period: Number of Participants With Treatment Discontinuation Due to AEs
- Description
An AE was any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptoms, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
- Time frame
- From study start to end of DBT period to at least 76 weeks
- Population
SAS included all participants who received at least one dose of study drug, with participants grouped according to treatment received. 3 participants in the prasinezumab arm and 1 participant in the placebo arm were randomized but not treated and 2 participants randomized to placebo arm received 1 dose of prasinezumab and were included in the prasinezumab arm for safety analysis.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
- NCT number
- NCT04777331
- Phases
- PHASE2
- Conditions
- Parkinsons Disease
- Interventions
- Prasinezumab, Placebo
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2025-12-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04777331?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04777331-2fbad496